NOVO NORDISK PHARMACEUTICALS A/S
CVR 24257924 · Public limited company (A/S) · Active · Low risk
NOVO NORDISK PHARMACEUTICALS A/S is a Public limited company (A/S), founded on , based in Bagsværd. The company is registered in the industry anden finansiel formidling i.a.n.. Our model estimates a bankruptcy risk of 0.0% over the next 12 months, which is 0.0 times the average for Danish companies. 20 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 12.3m and a net result of DKK 2.1m. CEO: Anders Rytter Mikkelsen.
Bankruptcy risk for NOVO NORDISK PHARMACEUTICALS A/S
0.0 × the average (1.41%) · higher risk than 6% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 24257924
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (52 years)
- Address
- c/o Novo Nordisk A/S, Novo Alle 1
2880 Bagsværd - Municipality
- Gladsaxe
- Industry
- Anden finansiel formidling i.a.n. (649990)
Bankruptcies in the industry: Ikke-finansielle holdingselskaber - Share capital
- DKK 1.0m
- Auditor
- DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 31 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 40.4% |
| Current ratio | 97% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 7 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 13 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -53k | DKK -46k | DKK -46k |
| Net profit | DKK 2.1m | DKK 6.9m | DKK -2.3m |
| Equity | DKK 12.3m | DKK 10.3m | DKK 103.3m |
| Total assets | DKK 30.5m | DKK 26.3m | DKK 111.2m |
| Cash | DKK 2.2m | DKK 1.5m | – |
| Short-term debt | DKK 18.2m | DKK 16.1m | – |
| Tax owed | DKK 26k | DKK 0 | – |
| Avg. employees | 0 | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Auditor's report on audited financial statements · DeloitteStatsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 159 | ||
| 1 Jan 2024 – 31 Dec 2024 | 154 | ||
| 1 Jan 2023 – 31 Dec 2023 | 156 | ||
| 1 Jan 2022 – 31 Dec 2022 | 145 | ||
| 1 Jan 2021 – 31 Dec 2021 | 140 | ||
| 1 Jan 2020 – 31 Dec 2020 | 146 | ||
| 1 Jan 2019 – 31 Dec 2019 | 154 | ||
| 1 Jan 2018 – 31 Dec 2018 | 147 | ||
| 1 Jan 2017 – 31 Dec 2017 | 135 | ||
| 1 Jan 2016 – 31 Dec 2016 | 129 | ||
| 1 Jan 2015 – 31 Dec 2015 | 131 | ||
| 1 Jan 2014 – 31 Dec 2014 | 117 | ||
| 1 Jan 2013 – 31 Dec 2013 | 208 | Late | |
| 1 Jan 2012 – 31 Dec 2012 | 125 | ||
| 1 Jan 2011 – 31 Dec 2011 | 134 | ||
| 1 Jan 2010 – 31 Dec 2010 | 129 | ||
| 1 Jan 2009 – 31 Dec 2009 | 111 | ||
| 1 Jan 2008 – 31 Dec 2008 | 117 | ||
| 1 Jan 2007 – 31 Dec 2007 | 122 | ||
| 1 Jan 2006 – 31 Dec 2006 | 126 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Anders Rytter Mikkelsen | Current | |
| CEO | Kurt Anker Nielsen | ||
| CEO | Mads Øvlisen | ||
| CEO | Karsten Munk Knudsen | ||
| CEO | Peter Bøggild | ||
| Board | Linette Tangsgaard Nielsen | Current | |
| Board | Naja Eilers Barrisøe | Current | |
| Board | Thomas Rask Nielsen | Current | |
| Board | Mads Ravn Sørensen | ||
| Board | Mads Øvlisen | ||
| Board | Bent Hauerberg | ||
| Board | Kurt Anker Nielsen | ||
| Board | Ole Falvig Ramsby | ||
| Board | Lars Rebien Sørensen | ||
| Board | Kåre Schultz | ||
| Board | Jesper Brandgaard | ||
| Board | Lars Fruergaard Jørgensen | ||
| Board | Lene Moth Bang | ||
| Board | Karsten Munk Knudsen | ||
| Board | Tomas Haagen | ||
| Board | Kristine Aachmann Bethe | ||
| Board | John Francis Kuckelman | ||
| Owner (100%) | NOVO NORDISK A/S | Current | |
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | PWCSP STATSAUTORISERET REVISIONSANPARTSSELSKAB | ||
| Auditor | Revisam | ||
| Auditor | PricewaterhouseCoopers, Statsautoriseret Revisionsinteressentskab | ||
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB |
The CEOs' other companies
Anders Rytter Mikkelsen – 9 other companies
- NOVO NORDISK GSC HOLDING A/S Active
- NOVO NORDISK INVEST 2 A/S Active
- NOVO NORDISK REGION AAMEO AND LATAM A/S Active
- NOVO NORDISK REGION CHINA A/S Active
- NOVO NORDISK REGION EUROPE A/S Active
- NOVO NORDISK REGION JAPAN & KOREA A/S Active
- Novo Nordisk Denmark A/S Active
- Novo Nordisk Invest 4 A/S Active
- Novo Nordisk North America Operations A/S Active
Kurt Anker Nielsen – 40 other companies, of which 2 bankrupt
- INCENTIVE A/S Bankrupt 17 Mar 2004
- OLICOM A/S Bankrupt 18 Jun 2010
- AKCB ApS Fusioneret
- ANPARTSSELSKABET AF 9. JANUAR 2002 Opløst
- BODENHOFF A/S Fusioneret
- COLOPLAST A/S Active
- D.C.P. AF 1988 A/S Opløst
- DAKO DENMARK ApS Active
- EJENDOMSSELSKABET SYDMARKEN 5 A/S Active
- FERROSAN ApS Active
- FERROSAN DANMARK A/S Fusioneret
- FERROSAN HOLDING A/S Fusioneret
- FERROSAN HOLDING A/S Fusioneret
- HAMELIN A/S Active
- HARNO INVEST A/S Opløst
- KAN ApS Opløst
- NNE A/S Active
- NNIT A/S Active
- NOVO NORDISK A/S Active
- NOVO NORDISK INVEST 1 A/S Opløst
- NOVO NORDISK INVEST 2 A/S Opløst
- NOVO NORDISK INVEST A/S Opløst
- NOVO NORDISK MEDICAL DEVICES A/S Fusioneret
- NOVO NORDISK RESEARCH & DEVELOPMENT A/S Opløst
- NOVOZYMES A/S Active
- NOVOZYMES BIOINDUSTRIAL A/S Active
- NOVOZYMES BIOINDUSTRIAL CHINA A/S Active
- Novo Holdings A/S Active
- Novo Nordisk Invest 3 A/S i Likvidation Opløst
- Novo Nordisk Pharmatech A/S Active
Mads Øvlisen – 15 other companies
- AKTIESELSKABET KJØBENHAVNS HANDELSBANK Fusioneret
- ApS KBUS 17 NR. 4108 Opløst
- DANSKE BANK A/S Active
- EGMONT HOLDING A/S Fusioneret
- EGMONT INTERNATIONAL HOLDING A/S Active
- EJENDOMSSELSKABET GOTHERSGADE 55 ApS Active
- EJENDOMSSELSKABET VOGNMAGERGADE 11 ApS Active
- KIRKBI A/S Active
- KIRKBI INVEST A/S Fusioneret
- LEGO A/S Active
- LEGO Foundation Investments A/S Active
- NOVO NORDISK A/S Active
- NOVO NORDISK INVEST 1 A/S Opløst
- NOVOZYMES BIOINDUSTRIAL A/S Active
- NOVOZYMES BIOINDUSTRIAL CHINA A/S Active
Karsten Munk Knudsen – 14 other companies
- 3SHAPE HOLDING A/S Active
- HEMPEL A/S Active
- NNE A/S Active
- NOVO NORDISK A/S Active
- NOVO NORDISK GSC HOLDING A/S Active
- NOVO NORDISK INVEST 2 A/S Active
- NOVO NORDISK PHARMA OPERATIONS A/S Active
- NOVO NORDISK REGION AAMEO AND LATAM A/S Active
- NOVO NORDISK REGION CHINA A/S Active
- NOVO NORDISK REGION EUROPE A/S Active
- NOVO NORDISK REGION JAPAN & KOREA A/S Active
- Novo Nordisk Denmark A/S Active
- Novo Nordisk Invest 4 A/S Active
- Novo Nordisk North America Operations A/S Active
Peter Bøggild – 12 other companies
- Anpartsselskabet af 21.08.2026 Opløst
- NNIT A/S Active
- NOVO NORDISK GSC HOLDING A/S Active
- NOVO NORDISK INVEST 2 A/S Active
- NOVO NORDISK REGION AAMEO AND LATAM A/S Active
- NOVO NORDISK REGION CHINA A/S Active
- NOVO NORDISK REGION EUROPE A/S Active
- NOVO NORDISK REGION JAPAN & KOREA A/S Active
- Novo Nordisk Invest 4 A/S Active
- Novo Nordisk North America Operations A/S Active
- PBGG Holding ApS Active
- TRIO INVEST ApS Opløst
Address history (2 moves)
| c/o Novo Nordisk A/S, Novo Alle 1, 2880 Bagsværd | |
| Novo Alle 1, 2880 Bagsværd | |
| Novo Alle, 2880 Bagsværd |
Former names
| NOVO NORDISK PHARMACEUTICALS A/S | – now |
| NOVO FARMAKA A/S | – |
Other companies at the same address
- NOVO NORDISK A/S Active
- NOVO NORDISK FARMAKA DANMARK A/S Opløst
- NOVO NORDISK GSC HOLDING A/S Active
- NOVO NORDISK INVEST 1 A/S Opløst
- NOVO NORDISK INVEST 2 A/S Active
- NOVO NORDISK PHARMA OPERATIONS A/S Active
- NOVO NORDISK REGION AAMEO AND LATAM A/S Active
- NOVO NORDISK REGION CHINA A/S Active
- NOVO NORDISK REGION EUROPE A/S Active
- NOVO NORDISK REGION JAPAN & KOREA A/S Active
- NOVO NORDISK SECURITY A/S Opløst
- Novo Nordisk Invest 4 A/S Active
- Novo Nordisk North America Operations A/S Active
Similar companies in Gladsaxe
- Selskabet af 24. marts 1982 A/S Søborg
- BYENS BOLIG ApS Søborg
- CELA INVEST ApS Bagsværd
- O.P.Poulsen ApS Søborg
- HMØ HOLDING ApS Søborg
- Northwave Capital ApS Søborg
- Schneekloth Invest ApS Søborg
- Okkels Invest ApS Søborg
- Soft Deis Invest ApS Søborg
- Rasimi ApS Søborg
- PTCL Holding ApS Søborg
- OU Invest ApS Søborg
Questions and answers about NOVO NORDISK PHARMACEUTICALS A/S
Has NOVO NORDISK PHARMACEUTICALS A/S gone bankrupt?
No, NOVO NORDISK PHARMACEUTICALS A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of NOVO NORDISK PHARMACEUTICALS A/S?
Our model estimates a bankruptcy risk of 0.0% over the next 12 months (low risk), which is 0.0 times the average for Danish companies.
Who is the CEO of NOVO NORDISK PHARMACEUTICALS A/S?
Anders Rytter Mikkelsen is the CEO of NOVO NORDISK PHARMACEUTICALS A/S.
Who is the auditor of NOVO NORDISK PHARMACEUTICALS A/S?
NOVO NORDISK PHARMACEUTICALS A/S most recently used DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was NOVO NORDISK PHARMACEUTICALS A/S founded?
NOVO NORDISK PHARMACEUTICALS A/S was founded on 4 April 1974.
What is the equity of NOVO NORDISK PHARMACEUTICALS A/S?
Equity was DKK 12.3m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.